Drug Use Analysis on Over-60-year Outpatients with Lung Cancer in the West China Hospital of Sichuan University in 2011_Chinese Journal of Evidence-Based Medicine

Authors：

 WUBin ¹ ,  XUTing ¹ ,  LIYou-ping ² , LUJing ¹ , ZHANGYing ¹ , ZHANMei ¹ , YINXi ¹ , XIAOGui-rong ¹

1. Department of Pharmacy, West China Hospital, Sichuan University, Chengdu 610041, China;
2. Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu 610041, China;

Corresponding author：

XUTing, Email: tingx2009@163.com; LIYou-ping, Email: yzmylab@hotmail.co

Keywords：

Lung cancer; Elderly; Outpatient; Drug use analysis; West China Hospital of Sichuan University

DOI：

10.7507/1672-2531.20140188

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To retrospectively investigate the medication structure and evaluate the rationality among over-60-year outpatients with lung cancer in the West China Hospital of Sichuan University in 2011. Methods The data was extracted from the hospital information system (HIS). Excel 2010 software was used for statistical analysis. Results a) The total of over-60-year outpatients with lung cancer were 17 296 person-times, of which 12 606 persons-times patients with no medication accounted for 72.88%. The monotherapy in patients with medication accounted for 75.76%. b) There were 5 types of tumour related drugs, including 56 kinds of different drugs, and the total frequency was 6 460 and the average cost was 2 219.38 yuan. The first three drugs classified by 5 types were traditional Chinese drugs (TCM, 28.50%), other therapy (24.91%), and etiological treatment (22.23%). c) For etiological treatment, tyrosine kinase inhibitors (TKI) accounted for 59.96%, and the first three drugs were gefitinib, recombinant human endostatin, and erlotinib. d) For symptomatic treatment, analgesic drugs accounted for 43.65%; and the first three drugs were tramadol hydrochloride sustained-release tablets, sodium zoledronic oxycodone, and acetaminophen. e) For ADR therapy, liver drugs accounted for 40.97%; and the first three drugs were palonosetron hydrochloride, licorice, and diammonium pantoprazole. f) Other treatment involved immunopotentiating drugs and hematopoietic growth factors, the ratios were 62.65% and 37.35%, and the first three drugs were thymalfasin, thymopentin, and recombinant interleukin-11. g) Huisheng, Banao capsule and Bailing capsule were at the first three usage in TCM, the ratios of which were 51.06%, 15.37%, and 13.91%. h) The top ten drugs were Huisheng oral liquid, gefitinib and thymus AFP, thymopentin recombinant interleukin-11, chelating compound spot capsules, recombinant human endostatin, tramadol hydrochloride extended release tablets, sodium, zole dronic, and Bailing capsule. Conclusion The antitumor therapies were mainly TKI single drug regimen for over-60-year outpatients with lung cancer in the West China hospital of Sichuan University in 2011. The most frequently used adjuvant therapies are antalgic, antitussive and skeletal related events prevention drugs. Besides, Chinese patent medicines are in common use as well.

Citation： WUBin, XUTing, LIYou-ping, LUJing, ZHANGYing, ZHANMei, YINXi, XIAOGui-rong. Drug Use Analysis on Over-60-year Outpatients with Lung Cancer in the West China Hospital of Sichuan University in 2011. Chinese Journal of Evidence-Based Medicine, 2014, 14(10): 1165-1170. doi: 10.7507/1672-2531.20140188 Copy

1.	伏绍宏, 李俊霞.四川省人口老龄化及老龄产业发展态势及对策研究.理论与改革, 2012, 5(4):77-79.
2.	徐珽, 卢静, 李幼平, 等. 2011年四川大学华西医院老年患者门诊疾病构成调查.中国循证医学杂志, 2013, 13(5):536-542.
3.	徐珽, 吴斌, 李幼平, 等. 2011年四川大学华西医院老年患者住院疾病构成调查.中国循证医学杂志, 2013, 13(6):680-686.
4.	Available at: http://apps.who.int/classifications/icd10/browse/2010/en.
5.	Fukihara J, Watanabe N, Taniguchi H. Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer. Oncology, 2014, 86(2):86-93.
6.	杨晓军, 李朝晖.采用DDD和DUI法分析我院门诊抗感染药物利用情况.现代应用药学, 1997, 14(1):60-62.
7.	Scagliotti GV, Parikh P, Pawel J, et al. Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage. J Clin Oncol, 2008; 26:3543-3551.
8.	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Non-small cell lung cancer, Version 2. 2012.
9.	Yoshida T, Yamada K, Azuma K, et al. Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer:a retrospective analysis. Med Oncol, 2013; 30(1):349-356.
10.	蔡芸, 闫丽莎, 魏宇宁, 等.王睿我院复方镇痛药氨酚羟考酮的临床应用分析.中国新药杂志, 2009, 9:862-864.
11.	聂海, 彭超, 郝杰, 等.唑来膦酸预防绝经妇女骨质疏松性骨折的Meta分析.第二军医大学学报, 2011, 32(9):985-990.
12.	时红萍, 侯仰韶, 张秋宁, 等.唑来膦酸联合化疗治疗非小细胞肺癌骨转移的Meta分析.实用肿瘤杂志, 2014, 29(1):55-61.
13.	时红萍, 张秋宁, 刘国庆, 等.唑来膦酸联合放射治疗治疗恶性肿瘤骨转移的Meta分析.中国循证医学杂志, 2013, 13(7):858-867.
14.	石晶, 付凌雨, 刘云鹏, 等.唑来膦酸和帕米膦酸二钠治疗骨转移癌疼痛疗效比较的Meta分析.中华临床医师杂志(电子版), 2011, 5(17):5051-5056.
15.	王涛, 宋三泰, 江泽飞, 等.伊班膦酸治疗恶性肿瘤性高钙血症的临床研究.中华肿瘤杂志, 2004, 26(12):739-741.
16.	邢镨元, 冯奉仪.伊班膦酸钠治疗恶性肿瘤骨转移临床评价.癌症进展杂志, 2008, 6(1):11-15.
17.	陈鹏宇.唑来膦酸与帕米膦酸二钠治疗恶性肿瘤所致高钙血症的疗效比较.南昌大学学报(医学版), 2011, 51(9):33-36.
18.	王凯, 王栓科, 赵斌, 等.唑来膦酸与帕米膦酸二钠治疗恶性肿瘤骨转移疼痛:疗效与安全性对比的Meta分析.中国组织工程研究与临床康复, 2010, 14(26):4791-4795.
19.	库建伟, 苗松玉, 李汝敏.不同止吐方案预防化疗所致呕吐的对比研究.河南肿瘤学杂志, 2003, 16(2):145-146.
20.	董爽, 于世英.肿瘤化疗所致恶心呕吐现状调查.中国循证医学杂志, 2013, 13(6):687-691.
21.	陈世灵.胸腺肽制剂在肿瘤治疗中的应用.中国医药导报, 2010, 15:9-10.

1. 伏绍宏, 李俊霞.四川省人口老龄化及老龄产业发展态势及对策研究.理论与改革, 2012, 5(4):77-79.
2. 徐珽, 卢静, 李幼平, 等. 2011年四川大学华西医院老年患者门诊疾病构成调查.中国循证医学杂志, 2013, 13(5):536-542.
3. 徐珽, 吴斌, 李幼平, 等. 2011年四川大学华西医院老年患者住院疾病构成调查.中国循证医学杂志, 2013, 13(6):680-686.
4. Available at: http://apps.who.int/classifications/icd10/browse/2010/en.
5. Fukihara J, Watanabe N, Taniguchi H. Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer. Oncology, 2014, 86(2):86-93.
6. 杨晓军, 李朝晖.采用DDD和DUI法分析我院门诊抗感染药物利用情况.现代应用药学, 1997, 14(1):60-62.
7. Scagliotti GV, Parikh P, Pawel J, et al. Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage. J Clin Oncol, 2008; 26:3543-3551.
8. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Non-small cell lung cancer, Version 2. 2012.
9. Yoshida T, Yamada K, Azuma K, et al. Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer:a retrospective analysis. Med Oncol, 2013; 30(1):349-356.
10. 蔡芸, 闫丽莎, 魏宇宁, 等.王睿我院复方镇痛药氨酚羟考酮的临床应用分析.中国新药杂志, 2009, 9:862-864.
11. 聂海, 彭超, 郝杰, 等.唑来膦酸预防绝经妇女骨质疏松性骨折的Meta分析.第二军医大学学报, 2011, 32(9):985-990.
12. 时红萍, 侯仰韶, 张秋宁, 等.唑来膦酸联合化疗治疗非小细胞肺癌骨转移的Meta分析.实用肿瘤杂志, 2014, 29(1):55-61.
13. 时红萍, 张秋宁, 刘国庆, 等.唑来膦酸联合放射治疗治疗恶性肿瘤骨转移的Meta分析.中国循证医学杂志, 2013, 13(7):858-867.
14. 石晶, 付凌雨, 刘云鹏, 等.唑来膦酸和帕米膦酸二钠治疗骨转移癌疼痛疗效比较的Meta分析.中华临床医师杂志(电子版), 2011, 5(17):5051-5056.
15. 王涛, 宋三泰, 江泽飞, 等.伊班膦酸治疗恶性肿瘤性高钙血症的临床研究.中华肿瘤杂志, 2004, 26(12):739-741.
16. 邢镨元, 冯奉仪.伊班膦酸钠治疗恶性肿瘤骨转移临床评价.癌症进展杂志, 2008, 6(1):11-15.
17. 陈鹏宇.唑来膦酸与帕米膦酸二钠治疗恶性肿瘤所致高钙血症的疗效比较.南昌大学学报(医学版), 2011, 51(9):33-36.
18. 王凯, 王栓科, 赵斌, 等.唑来膦酸与帕米膦酸二钠治疗恶性肿瘤骨转移疼痛:疗效与安全性对比的Meta分析.中国组织工程研究与临床康复, 2010, 14(26):4791-4795.
19. 库建伟, 苗松玉, 李汝敏.不同止吐方案预防化疗所致呕吐的对比研究.河南肿瘤学杂志, 2003, 16(2):145-146.
20. 董爽, 于世英.肿瘤化疗所致恶心呕吐现状调查.中国循证医学杂志, 2013, 13(6):687-691.
21. 陈世灵.胸腺肽制剂在肿瘤治疗中的应用.中国医药导报, 2010, 15:9-10.

Next Article
Drug Use Analysis on Over-60-year Inpatients with Lung Cancer in the West China Hospital of Sichuan University in 2011

Chinese Journal of Evidence-Based Medicine

Drug Use Analysis on Over-60-year Outpatients with Lung Cancer in the West China Hospital of Sichuan University in 2011

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content